ropeginterferon alfa-2b-njft
| Brand name | Besremi |
|---|---|
| Active ingredient | ropeginterferon alfa-2b-njft |
| Strength | 500MCG/0.5ML |
| Dosage form | Injection |
| Route | Subcutaneous |
| Modality | Biologic |
| FDA approval | June 2026 |
| Marketing status | Rx |
Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.